July 14, 2009 Contact: Eleanor Blume Phone: 781.640.7750 Email: [email protected] For Immediate Release STUDENT GROUPS AND CONSUMER ADVOCATES DEMAND WITHDRAWAL OF UNIVERSITY SUPPORT FOR HARMFUL LEGISLATION Legislation Would Delay Affordable Medicines in the United States and Abroad
BERKELEY – Today, the American Medical Student Association, Essential Action, and Universities Al ied for Essential Medicines (UAEM) joined together in demanding that the
Association of American Universities (AAU) withdraw its endorsement of H.R. 1548, the
“Pathway for Biosimilars Acts” in a letter sent to AAU President Robert Berdahl.1 AAU has
so far resisted cal s to rescind its support of the unjustifiably long twelve years of brand exclusivity permitted by the bil . Such a monopoly period would delay the introduction of
generic versions of biologics (cal ed fol ow-on biologics or biosimilars) which include
vaccines as well as life-saving cancer, arthritis, and diabetes drugs, keeping medicine prices
high and out of the hands of many consumers in the U.S. and developing countries. The groups are also asking Congress to include a reasonable period of exclusivity that will
safeguard affordable access. Small molecule medicines such as Prilosec have exclusivity
Economic analyses have repeatedly refuted the AAU’s claim, repeated by the Biotechnology
Industry Organization (BIO), that twelve years of exclusivity are needed for sufficient cost
recovery to sustain innovation. A recent paper by the Federal Trade Commission estimates
that the introduction of fol ow-on biologics would generate tremendous savings on the $40.3 bil ion U.S. consumers spend on biologics each year, some of which cost tens of thousands
of dol ars per course of treatment.2 The extended exclusivity terms in H.R. 1548 and several
other legislative proposals would maximize royalties from biologics patents licensed by
universities, which are non-profit institutions, at the cost of access. “AAU’s support for H.R. 1548 truly threatens the core identity of universities as non-profit
organizations dedicated to the creation and dissemination of knowledge for the public
good,” said Ethan Guil en, Executive Director of UAEM. Each year the federal government – that is, U.S. taxpayers – provides bil ions of dol ars in
research support, accounting for more than 60% of university research budgets. It is
unconscionable for federal y funded universities, represented by AAU, to so cal ously
1 http://www.aau.edu/WorkArea/DownloadAsset.aspx?id=9016 2 See Federal Trade Commission, Emerging Health Care Issues: Fol ow-On Biologic Drug Competition, June 2009. Available at: http://www.ftc.gov/opa/2009/06/biologics.shtm and Henry Grabowski, Outlook: Fol ow-on biologics: data exclusivity and the balance between innovation and competition. Nature Reviews Drug Discovery 7, 479-488 (June 2008). Available at: http://www.nature.com/nrd/journal/v7/n6/ful /nrd2532.html.
UNIVERSITIES ALLIED FOR ESSENTIAL MEDICINES
obstruct taxpayer access to their life-saving therapeutics. This contradiction is even more
poignant at a time when individuals and the federal government struggle to control
bal ooning healthcare costs. An excessive term of exclusivity wil further impede affordable
access to critical vaccines, including potential y those for pandemic flu outbreaks. For those ten mil ion people, primarily in developing countries, who die every year because they do not
have access to basic medicine, the exclusivity terms in H.R. 1548 wil further exacerbate the
access gap by delaying the onset of lower-cost fol ow-on biologics, including critically
needed vaccines. Developing a process for getting biosimilars to market is a critical step to furthering access
to affordable medicines. However, in regards to exclusivity terms, universities must show
courage in adopting evidence-based stances that benefit society, and not simply act as echo chambers for PhRMA and BIO priorities. Alternate proposals currently being considered
include the “Promoting Innovation and Access to Life-Saving Medicine Act” introduced in
both the House (H.R. 1427) and the Senate (S.726), proposing a five year exclusivity term,
and several proposals for a seven year exclusivity term. Which one of these competing proposals -- 12 to 14 years or five to seven years -- succeeds wil shape access to life-saving
medicines in the U.S. and abroad and the ability of our health system to control bal ooning
The letter to the AAU is available at: http://www.essentialmedicine.org/uaem-amsa-and-
essential-action-demand-aau-rescind-support-of-excessive-data-exclusivity/
About UAEM
Universities Al ied for Essential Medicines (UAEM) is a coalition of students at over 40 top
research institutions across the United States, Canada, the United Kingdom, and Germany. UAEM’s mission is to ensure that people in developing countries have access to medicines
developed in universities and that university medical research addresses the needs of the
majority of the world’s population. As an organization which values innovation, we work to
empower students to find new ways to improve access to health throughout the world. www.essentialmedicine.org
About the American Medical Student Association
The American Medical Student Association (AMSA), with more than a half-century history of medical student activism, is the oldest and largest independent association of physicians-
in-training in the United States. Founded in 1950, AMSA is a student-governed, non-profit
organization committed to representing the concerns of physicians-in-training. With more
than 62,000 members, including medical and premedical students, residents and practicing physicians, AMSA is committed to improving medical training as wel as advancing the
profession of medicine. AMSA focuses on four strategic priorities, including advocating for
quality, affordable health care for al , global health equity, enriching medicine through
diversity and professional integrity, development and student wel being. To learn more about AMSA, our strategic priorities, or joining the organization, please visit us online at
UNIVERSITIES ALLIED FOR ESSENTIAL MEDICINES
About Essential Action
Essential Action is a public health and corporate accountability group located in
FOLLICULOGENESIS IN CATTLE J.P. Kastelic Lethbridge Research Centre, Box 3000, Lethbridge, AB, Canada T1J 4B1 PRENATAL FOLLICULAR GROWTH Development of oocytes and follicles begins in utero. Primordial germ cells proliferate by mitosis to form primary oocytes; the first meiotic prophase starts between Days 75 and 80 of pregnancy (Erickson, 1966). At the diplotene stage of meiosis (a